- Home
- FORA vs RPTX Comparison
FORA vs RPTX Comparison
Compare FORA & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- RPTX
- Stock Information
- Founded
- FORA 2014
- RPTX 2016
- Country
- FORA United States
- RPTX Canada
- Employees
- FORA N/A
- RPTX N/A
- Industry
- FORA Computer Software: Prepackaged Software
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- RPTX Health Care
- Exchange
- FORA Nasdaq
- RPTX Nasdaq
- Market Cap
- FORA 69.4M
- RPTX 69.2M
- IPO Year
- FORA N/A
- RPTX 2020
- Fundamental
- Price
- FORA $2.31
- RPTX $1.77
- Analyst Decision
- FORA Strong Buy
- RPTX Strong Buy
- Analyst Count
- FORA 1
- RPTX 3
- Target Price
- FORA $5.00
- RPTX $4.50
- AVG Volume (30 Days)
- FORA 76.2K
- RPTX 96.2K
- Earning Date
- FORA 11-12-2025
- RPTX 11-06-2025
- Dividend Yield
- FORA N/A
- RPTX N/A
- EPS Growth
- FORA N/A
- RPTX N/A
- EPS
- FORA N/A
- RPTX N/A
- Revenue
- FORA $25,031,040.00
- RPTX $250,000.00
- Revenue This Year
- FORA $47.82
- RPTX N/A
- Revenue Next Year
- FORA $10.11
- RPTX N/A
- P/E Ratio
- FORA N/A
- RPTX N/A
- Revenue Growth
- FORA 18.59
- RPTX N/A
- 52 Week Low
- FORA $1.64
- RPTX $0.89
- 52 Week High
- FORA $4.03
- RPTX $4.07
- Technical
- Relative Strength Index (RSI)
- FORA 62.63
- RPTX 65.37
- Support Level
- FORA $2.20
- RPTX $1.66
- Resistance Level
- FORA $2.39
- RPTX $1.83
- Average True Range (ATR)
- FORA 0.13
- RPTX 0.07
- MACD
- FORA 0.02
- RPTX 0.00
- Stochastic Oscillator
- FORA 83.33
- RPTX 74.00
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.